Synapse - Clinical next generation sequencing (NGS) of esophagogastric (EG) adenocarcinomas identifies distinct molecular signatures of response to HER2 inhibition, first-line 5FU/platinum and PD1/CTLA4 blockade

Clinical next generation sequencing (NGS) of esophagogastric (EG) adenocarcinomas identifies distinct molecular signatures of response to HER2 inhibition, first-line 5FU/platinum and PD1/CTLA4 blockade Meeting Abstract

Authors:	Janjigian, Y. Y.; Sanchez-Vega, F.; Jonsson, P.; Tuvy, Y.; Bouvier, N.; Riches, J.; Kundra, R.; Ku, G.; Hechtman, J. F.; Kelsen, D.; Tang, L.; Ilson, D.; Vakiani, E.; Stadler, Z.; Callahan, M.; Solit, D. B.; Berger, M. F.; Taylor, B. S.; Schultz, N.
Abstract Title:	Clinical next generation sequencing (NGS) of esophagogastric (EG) adenocarcinomas identifies distinct molecular signatures of response to HER2 inhibition, first-line 5FU/platinum and PD1/CTLA4 blockade
Meeting Title:	41st European Society for Medical Oncology Congress (ESMO)
Journal Title:	Annals of Oncology
Volume:	27
Issue:	Suppl. 6
Meeting Dates:	2016 Oct 7-11
Meeting Location:	Copenhagen, Denmark
ISSN:	0923-7534
Publisher:	Oxford University Press
Date Published:	2016-10-01
Start Page:	vi208
Language:	English
ACCESSION:	WOS:000393912500609
DOI:	10.1093/annonc/mdw371.04
PROVIDER:	wos
Notes:	Meeting Abstract: 612O -- Source: Wos